E
HAE icon

Ergoteles’s Haemonetics HAE Stock Holding History

Ergoteles’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,634
Closed -$991K – 388
2023
Q2 		$991K Buy
+11,634
New +$984K 0.05% 468
2023
Q1 		– Sell
-12,180
Closed -$958K – 1447
2022
Q4 		$958K Buy
12,180
+2,153
+21% +$173K 0.04% 473
2022
Q3 		$742K Buy
+10,027
New +$720K 0.03% 609
2021
Q1 		– Sell
-2,000
Closed -$238K – 906
2020
Q4 		$238K Buy
+2,000
New +$215K 0.01% 570

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Ergoteles's HAE Position: Q3 2023 in Review

Ergoteles sold out of Haemonetics (HAE) in Q3 2023, closing a stake of 11,634 shares — an estimated $991K sold.

Ergoteles first reported a position in HAE in Q4 2020 and held it in 4 quarters. The position peaked at $991K in Q2 2023. 296 funds tracked by Wall St. Rank hold HAE as of Q3 2023.

  • Ergoteles reported no remaining Haemonetics position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 11,634 Haemonetics shares in Q3 2023, an estimated $991K.
  • Ergoteles first reported a position in Haemonetics in Q4 2020 and held it in 4 quarters.
  • Ergoteles's Haemonetics position peaked at $991K in Q2 2023.
  • 296 funds tracked by Wall St. Rank held Haemonetics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.